4.6 Review

The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the Hematological Patient: A Systematic Review and Meta-Analysis

Journal

JOURNAL OF FUNGI
Volume 9, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/jof9060674

Keywords

invasive pulmonary aspergillosis; galactomannan; serum; broncho-alveolar lavage; hematology; malignancy; systematic review; meta-analysis

Ask authors/readers for more resources

This article conducts a systematic review and meta-analysis to determine the optimal cut-off values of the optical density index (ODI) for galactomannan antigen assays (GM) in diagnosing invasive pulmonary aspergillosis in hematological patients. The study found that a serum ODI of 0.5 and BAL ODI of 1.0 were the most suitable cut-off values for clinical practice. However, the evidence for the use of GM in clinical practice for hematological malignancy patients is currently insufficient.
The optimal cut-off value of the optical density index of the galactomannan antigen assays (GM) for diagnosing invasive pulmonary aspergillosis in hematological patients is a disputed topic. This article conducts a systematic review with a meta-analysis to establish which optical density index (ODI) cut-off value should be implemented into clinical practice. Pubmed, Embase and Cochrane databases were searched (N = 27). The pooled data, using a generalized linear mixed model with binomial distribution, resulted in an overall serum sensitivity of 0.76 and a specificity of 0.92. For serum ODI 0.5 there was a pooled sensitivity of 0.92 and a specificity of 0.84. The pooled data of all broncho-alveolar lavage (BAL) studies resulted in an overall sensitivity of 0.80 and a specificity of 0.95. For BAL ODI 0.5, there was a pooled sensitivity of 0.75 and a specificity of 0.88. For the BAL ODI 1.0 pooling, the studies resulted in a sensitivity of 0.75 and a specificity of 0.96. Serum ODI of 0.5 and BAL ODI of 1.0 are the most suitable cut-offs for clinical practice. However, our study affirms that the evidence for the use of GM in clinical practice for the hematological malignancy patient is currently insufficient and more research is needed to determine the diagnostic value of GM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available